MedTrace Logo

Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients

NCT04910295 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 112

Last updated 2023-04-12

No results posted yet for this study

Summary

Serum antibody titre against COVID-19 spike protein will be measured before, after the first dose, and after the second dose (when applicable) in cancer patients who are receiving or received anti-cancer drugs. Side effects of vaccination and actual incidence of COVID-19 will be monitored.

Conditions

Interventions

DRUG

COVID-19 vaccine

Subjects will be vaccinated with COVID-19 vaccines approved in Korea. Data on specific vaccines will be gathered.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-26
Primary Completion
2022-04-30
Completion
2022-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04910295 on ClinicalTrials.gov